{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T13:07:39Z","timestamp":1769692059358,"version":"3.49.0"},"reference-count":12,"publisher":"American Society of Consultant Pharmacists","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["sr care pharm"],"published-print":{"date-parts":[[2023,1,1]]},"abstract":"<jats:p><jats:bold>Objective<\/jats:bold> Describe the incidence of delirium and associated outcomes among hospitalized, non-critically ill older people.  <jats:bold>Design<\/jats:bold> Single-center, retrospective chart review.  <jats:bold>Setting<\/jats:bold> A 217-bed academic teaching hospital in Cambridge, Massachusetts\n affiliated with Harvard Medical School.  <jats:bold>Patients<\/jats:bold> People 65 years of age or older, admitted to a general medicine unit between January 1 and August 31, 2021, who were prescribed one or more deliriogenic medications prior to or during admission.  <jats:bold>Interventions<\/jats:bold>\n Patient electronic medical records were reviewed for deliriogenic medications prescribed and administered during admission and associated clinical outcomes.  <jats:bold>Results<\/jats:bold> The percentage of patients who developed delirium was 13% overall. The most implicated deliriogenic medications\n were benzodiazepines, antipsychotics, and histamine-2 receptor antagonists (H2RAs). Seventy-three percent of deliriogenic home medications were continued upon admission. Subgroup analyses of those with delirium had a mean length-of-stay of 20 days compared with 6 days in those who did not\n develop delirium. Those with delirium tended to have more deliriogenic medications used during admission.  <jats:bold>Conclusion<\/jats:bold> This review describes the incidence of delirium for non-critically ill older people who were prescribed at least one deliriogenic medication. Of all the\n deliriogenic agents reviewed, moderate quality clinical evidence supports the association between use and development of delirium except for H2RAs, which have low-quality evidence. Pharmacist-driven efforts to deprescribe deliriogenic medications in at-risk patient populations may be better\n focused on agents with higher-quality evidence.<\/jats:p>","DOI":"10.4140\/tcp.n.2023.21","type":"journal-article","created":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T15:23:09Z","timestamp":1672240989000},"page":"21-28","source":"Crossref","is-referenced-by-count":2,"title":["Deliriogenic Medication Prescribing and Delirium in Hospitalized, Non-Critically Ill Older People"],"prefix":"10.4140","volume":"38","author":[{"given":"Shane J.","family":"Softy","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Mount Auburn Hospital, Cambridge, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Rogers","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Mount Auburn Hospital, Cambridge, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Voronina","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Mount Auburn Hospital, Cambridge, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"Brueckner","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Mount Auburn Hospital, Cambridge, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2625","reference":[{"issue":"12","key":"ref1","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1111\/jgs.16768","article-title":"Multicomponent interventions for the prevention of delirium in hospitalized older people: a meta-analysis.","volume":"68","year":"2020","journal-title":"J Am Geriatr Soc."},{"issue":"10","key":"ref2","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1176\/appi.ajp.2018.18070893","article-title":"Delirium.","volume":"176","year":"2019","journal-title":"Am J Psychiatry."},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1186\/s12877-020-01723-4","article-title":"A call to action for delirium research: meta-analysis and regression of delirium associated mortality.","volume":"20","year":"2020","journal-title":"BMC Geriatr."},{"issue":"12","key":"ref4","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.amjmed.2019.05.035","article-title":"Initiative for prevention and early identification of delirium in medical-surgical units: lessons learned in the past five years.","volume":"132","year":"2019","journal-title":"Am J Med."},{"issue":"4","key":"ref5","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/jgs.15767","article-title":"American Geriatrics Society 2019 Updated AGS Beers Criteria\u00ae for Potentially Inappropriate Medication Use in Older Adults.","volume":"67","journal-title":"J Am Geriatr Soc."},{"key":"ref6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2165\/00002512-199915010-00002","article-title":"Drug-induced cognitive impairment in the elderly.","volume":"15","year":"1999","journal-title":"Drugs Aging."},{"issue":"6","key":"ref7","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1097\/SLA.0000000000000742","article-title":"Geriatric assessment as a predictor of delirium and other outcomes in elderly patients with cancer.","volume":"261","year":"2015","journal-title":"Ann Surg."},{"issue":"10","key":"ref8","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11920-016-0727-9","article-title":"Benzodiazepine misuse in the elderly: risk factors, consequences, and management.","volume":"18","year":"2016","journal-title":"Curr Psychiatry Rep."},{"issue":"1","key":"ref9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s40520-015-0359-7","article-title":"Anticholinergic drugs and negative outcomes in the older population: from biological plausibility to clinical evidence.","volume":"28","year":"2016","journal-title":"Aging Clin Exp Res."},{"issue":"6","key":"ref10","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s40266-017-0455-9","article-title":"The comparative risk of delirium with different opioids: a systematic review.","volume":"34","year":"2017","journal-title":"Drugs Aging."},{"issue":"8","key":"ref11","doi-asserted-by":"crossref","first-page":"e0507","DOI":"10.1097\/CCE.0000000000000507","article-title":"Association of histamine-2 blockers and proton-pump inhibitors with delirium development in critically ill adults: a retrospective cohort study.","volume":"3","year":"2021","journal-title":"Crit Care Explor."},{"key":"ref12","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.genhosppsych.2021.07.010","article-title":"Delirium risk of histamine-2 receptor antagonists and proton pump inhibitors: a study based on the adverse drug event reporting database in Japan.","volume":"72","year":"2021","journal-title":"Gen Hosp Psychiatry."}],"container-title":["The Senior Care Pharmacist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ascp\/tscp\/2023\/00000038\/00000001\/art00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T04:47:16Z","timestamp":1705726036000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.4140\/TCP.n.2023.21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,1]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1,1]]}},"alternative-id":["2639-9636(20230101)38:1L.21;1-"],"URL":"https:\/\/doi.org\/10.4140\/tcp.n.2023.21","relation":{},"ISSN":["2639-9636"],"issn-type":[{"value":"2639-9636","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1,1]]}}}